Yujie Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yujie Deng has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Hai Song
The MOE Key Laboratory of Biosystems Homeostasis and Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, Hangzhou, China
2 shared publications Jinqiu Lu
The MOE Key Laboratory of Biosystems Homeostasis and Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, Hangzhou, Zhejiang, China
2 shared publicationsAiling Wu
Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University, Hangzhou, China
1 shared publication- Bin Zhao
Ministry of Education Key Laboratory of Biosystems Homeostasis and Protection and Zhejiang Key Laboratory of Molecular Cancer Biology, Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University
1 shared publication Cheng Liao
Department of Preclinical Development, Translation Medicine & External Research, Jiangsu Hengrui Medicine CO., LTD., Shanghai, China
1 shared publicationLiansheng Liu
Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University, Hangzhou, China
1 shared publication
Latest Publications
- Open Access
- 9 February 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100400
MEKK2 and MEKK3 orchestrate multiple signals to regulate Hippo pathway
- 9 February 2021
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 296, 100400
Open AccessMEKK2 and MEKK3 orchestrate multiple signals to regulate Hippo pathway
- 5 November 2018
- Published by Springer Nature in The EMBO Journal
- Vol. 38 (1) , e201899506
Loss of VGLL4 suppresses tumor PD‐L1 expression and immune evasion
Targeting immune checkpoints, such as PD‐L1 and its receptor PD‐1, has opened a new avenue for treating cancers. Understanding the regulatory mechanism of PD‐L1 and PD‐1 will improve the clinical response rate and efficacy of PD‐1/PD‐L1 blockade in cancer patients and the development of combinatorial strategies. VGLL4 inhibits YAP‐induced cell proliferation and tumorigenesis through competition with YAP for binding to TEADs. However, whether VGLL4 has a role in anti‐tumor immunity is largely unknown. Here, we found that disruption of Vgll4 results in potent T cell‐mediated tumor regression in murine syngeneic models. VGLL4 deficiency reduces PD‐L1 expression in tumor cells. VGLL4 interacts with IRF2BP2 and promotes its protein stability through inhibiting proteasome‐mediated protein degradation. Loss of IRF2BP2 results in persistent binding of IRF2, a transcriptional repressor, to PD‐L1 promoter. In addition, YAP inhibits IFNγ‐inducible PD‐L1 expression partially through suppressing the expression of VGLL4 and IRF1 by YAP target gene miR‐130a. Our study identifies VGLL4 as an important regulator of PD‐L1 expression and highlights a central role of VGLL4 and YAP in the regulation of tumor immunity. Synopsis Targeting the PD‐L1/PD‐1 pathway using antibodies is effective in the clinical treatment of a broad spectrum of cancers. Loss of VGLL4 elicits anti‐tumor immunity by downregulation of tumor PD‐L1 expression. Loss of Vgll4 inhibits murine tumor growth in syngeneic mice. Loss of VGLL4 decreases the expression of PD‐L1 in tumor cells. VGLL4 stabilizes IRF2BP2 through inhibiting proteasome mediated degradation of IRF2BP2. YAP inhibits IFNγ‐inducible PD‐L1 expression.
- 5 November 2018
- Published by Springer Nature in The EMBO Journal
- Vol. 38 (1) , e201899506
Loss of VGLL4 suppresses tumor PD‐L1 expression and immune evasion
Targeting immune checkpoints, such as PD‐L1 and its receptor PD‐1, has opened a new avenue for treating cancers. Understanding the regulatory mechanism of PD‐L1 and PD‐1 will improve the clinical response rate and efficacy of PD‐1/PD‐L1 blockade in cancer patients and the development of combinatorial strategies. VGLL4 inhibits YAP‐induced cell proliferation and tumorigenesis through competition with YAP for binding to TEADs. However, whether VGLL4 has a role in anti‐tumor immunity is largely unknown. Here, we found that disruption of Vgll4 results in potent T cell‐mediated tumor regression in murine syngeneic models. VGLL4 deficiency reduces PD‐L1 expression in tumor cells. VGLL4 interacts with IRF2BP2 and promotes its protein stability through inhibiting proteasome‐mediated protein degradation. Loss of IRF2BP2 results in persistent binding of IRF2, a transcriptional repressor, to PD‐L1 promoter. In addition, YAP inhibits IFNγ‐inducible PD‐L1 expression partially through suppressing the expression of VGLL4 and IRF1 by YAP target gene miR‐130a. Our study identifies VGLL4 as an important regulator of PD‐L1 expression and highlights a central role of VGLL4 and YAP in the regulation of tumor immunity. Synopsis Targeting the PD‐L1/PD‐1 pathway using antibodies is effective in the clinical treatment of a broad spectrum of cancers. Loss of VGLL4 elicits anti‐tumor immunity by downregulation of tumor PD‐L1 expression. Loss of Vgll4 inhibits murine tumor growth in syngeneic mice. Loss of VGLL4 decreases the expression of PD‐L1 in tumor cells. VGLL4 stabilizes IRF2BP2 through inhibiting proteasome mediated degradation of IRF2BP2. YAP inhibits IFNγ‐inducible PD‐L1 expression.